Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
Routine monitoring of anti-malarial drugs is recommended for early detection of drug resistance and to inform national malaria treatment guidelines. In Ethiopia, the national treatment guidelines employ a species-specific approach. Artemether-lumefantrine (AL) and chloroquine (CQ) are the first-line schizonticidal treatments for Plasmodium falciparum and Plasmodium vivax, respectively. The National Malaria Control and Elimination Programme in Ethiopia is considering dihydroartemisinin-piperaquine (DHA/PPQ) as an alternative regimen for P. falciparum and P. vivax.
The study assessed the clinical and parasitological efficacy of AL, CQ, and DHA/PPQ in four arms. Patients over 6 months and less than 18 years of age with uncomplicated malaria mono-infection were recruited and allocated to AL against P. falciparum and CQ against P. vivax. Patients 18 years or older with uncomplicated malaria mono-infection were recruited and randomized to AL or dihydroartemisinin-piperaquine (DHA/PPQ) against P. falciparum and CQ or DHA/PPQ for P. vivax. Patients were followed up for 28 (for CQ and AL) or 42 days (for DHA/PPQ) according to the WHO recommendations. Polymerase chain reaction (PCR)-corrected and uncorrected estimates were analysed by Kaplan Meier survival analysis and per protocol methods.
A total of 379 patients were enroled in four arms (n = 106, AL-P. falciparum; n = 75, DHA/PPQ- P. falciparum; n = 142, CQ-P. vivax; n = 56, DHA/PPQ-P. vivax). High PCR-corrected adequate clinical and parasitological response (ACPR) rates were observed at the primary end points of 28 days for AL and CQ and 42 days for DHA/PPQ. ACPR rates were 100% in AL-Pf (95% CI: 96–100), 98% in CQ-P. vivax (95% CI: 95–100) at 28 days, and 100% in the DHA/PPQ arms for both P. falciparum and P. vivax at 42 days. For secondary endpoints, by day three 99% of AL-P. falciparum patients (n = 101) cleared parasites and 100% were afebrile. For all other arms, 100% of patients cleared parasites and were afebrile by day three. No serious adverse events were reported.
This study demonstrated high therapeutic efficacy for the anti-malarial drugs currently used by the malaria control programme in Ethiopia and provides information on the efficacy of DHA/PPQ for the treatment of P. falciparum and P. vivax as an alternative option.
Malaria remains a disease of significant public health importance in Ethiopia despite the gains made through recent malaria control efforts. In 2020, the World Health Organization (WHO) estimated approximately 4.2 million malaria cases in Ethiopia with Plasmodium falciparum accounting for 77% of the confirmed cases . According to the Malaria Programme Review conducted by the WHO in April 2020, deaths due to malaria decreased 67%, from 9/100,000 to 3/100,000 population at risk, and the annual parasite incidence decreased 37%, from 19/1,000 to 12/1,000 population, between 2016 and 2019 . Building on this progress, Ethiopia aims to eliminate malaria by 2030 . Prompt case management with efficacious drugs plays a pivotal role in malaria control and elimination efforts . Artemether-lumefantrine (AL) is the current first-line anti-malarial medication for uncomplicated P. falciparum, and chloroquine (CQ) remains the first-line treatment for P vivax in Ethiopia. The second-line treatment for P. falciparum uncomplicated malaria is oral quinine and for uncomplicated P. vivax malaria is AL . The Ethiopian Ministry of Health (MOH) is considering dihydroartemisinin-piperaquine (DHA/PPQ) as an alternative regimen and seeks to generate safety and efficacy data in Ethiopia prior to any policy changes.
The Ethiopian Public Health Institute (EPHI), collaborating with local and international partners (WHO and U.S. President’s Malaria Initiative (PMI)), has been monitoring the therapeutic efficacy of anti-malarial drugs that may be used for malaria management in the country. With the exception of data from a location in Arbaminch in 2008, where efficacy was reported to be 92.5% (Personal communication, Moges Kassa), AL efficacy remained greater than 95% against uncomplicated P. falciparum throughout the country since the beginning of its use in 2004 [6,7,8,9,10]. However, the evidence of resistance to artemisinins in Southeast Asia and emergence of an artemisinin-resistance-associated mutation in Rwanda underscores the need for continued surveillance [11, 12]. Chloroquine-resistant P. vivax has remained rare in Africa. In Ethiopia, CQ efficacy remains above 95% although sporadic reports of CQ failure suggest emerging resistance [8, 13,14,15,16,17,18,19,20]. There are limited data in Ethiopia on the efficacy of other artemisinin-based combinations.
Although DHA/PPQ is a WHO-recommended treatment for malaria (regardless of species) and the first-line therapy in many countries in Asia and Africa, its efficacy has not been evaluated in Ethiopia to date. It has been demonstrated to be highly effective against both P. falciparum and P. vivax and well-tolerated in Africa and Asia [21,22,23,24,25]. Gastrointestinal distress and dizziness are the most commonly reported adverse events . QT prolongation without clinical abnormalities or cardiac toxicity has also been noted .
This study reports the therapeutic efficacy of AL or DHA/PPQ against uncomplicated P. falciparum and CQ or DHA/PPQ against uncomplicated P. vivax to provide on-going, evidence-based recommendations for the national malaria treatment guidelines.
The study evaluated adequate clinical and parasitological responses (ACPR) to standard therapeutic doses of AL or DHA/PPQ in patients with uncomplicated P. falciparum and CQ or DHA/PPQ in patients with uncomplicated P. vivax.
Study area and population
The study was conducted in two sentinel sites in Ethiopia: (1) Felegeselam Health Centre, Pawe, Metekel Zone, Benishangul Gumuz Region and (2) Arbaminch Health Centre, Gamu-Gofa Zone, Southern Nations and Nationalities Peoples’ (SNNP) Region (Fig. 1). Felegeselam Health Centre is located 589 km from Addis Ababa in northwestern Ethiopia. Arbaminch Health Centre is located about 500 km southwest of Addis Ababa. Therapeutic efficacy studies have been conducted in these areas previously: 2008 and 2011 in Arbaminch, and 2010 and 2013 in Pawe.
The study areas have moderate malaria transmission and malaria affects all age groups. Plasmodium falciparum and P. vivax co-exist at these sites, with P. falciparum being the predominant species. Anopheles arabiensis is the primary malaria vector. The study was conducted September–December 2017 during the major malaria transmission season.
Study design and participants
The study was designed as an open label, four arm trial conducted in two sites (P. falciparum-AL, P. falciparum-DHA/PPQ, P. vivax-CQ and P. vivax-DHA/PPQ arms). The study was based on the WHO recommendations for designing surveillance studies on anti-malarial drug efficacy . Patients presenting to the outpatient department with mono-infection for P. falciparum or P. vivax were enroled in the study. Plasmodium falciparum-infected patients 18 years of age and above were randomized to the AL or DHA/PPQ arms. All patients with P. falciparum older than six months and younger than 18 years were enroled in the AL arm. Similarly, patients with P. vivax 18 years of age and above were randomized to the CQ or DHA/PPQ arms. All patients older than six months and younger than 18 years were enroled in the CQ arm. Enrolment to DHA/PPQ arms were limited to adults 18 years of age and above as per the guidance of the Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA).
The WHO recommendations for inclusion and exclusion were followed with the notable addition of weight ≥ 5 kg based on WHO dosing recommendations, lowering of the minimal enroling P. falciparum asexual parasite count from 1,000 to 500 parasites/µL based on local transmission, and the addition of a residency restriction of within 20 km from the enroling health facility to facilitate visiting the patient if needed . All participants or their guardian/caregiver agreed to the finger prick sampling and provided written informed consent/assent.
Coordination and quality control
The study was coordinated and implemented by EPHI and ICAP at Columbia University in Addis Ababa, Ethiopia. A three-day training of trainers (TOT) was conducted to review the study protocol for the central study team. The site teams comprised of six people per site: two clinicians, two laboratory technologists, a porter/tracer, and a supervisor. The central team provided on-site training and supervision for the first two weeks of study enrolment. The site teams received additional regular supportive supervision throughout the study period.
Treatment and follow up
Patients with P. falciparum enroled in the study were treated with either AL or DHA/PPQ (if ≥ 18 years of age), and patients with P. vivax were treated with either CQ or DHA/PPQ (if ≥ 18 years of age). Artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine; Novartis Pharmaceuticals Corporation, New York, NY, US) was administered twice daily for three days, and DHA/PPQ (40 mg DHA and 640 mg PPQ), Duo-CotecxinR, Holley-Cotec Pharmaceuticals, China) was administered once daily for 3 days according to the manufacturers’ recommendations. CQ (Micro Labs Limited, Tamil Nadu, India) was prescribed according to national treatment guidelines at 25 mg base/kg over 3 days (10 mg base/kg on days 0 and 1, and 5 mg base/kg on day 2). All study drugs were provided by the WHO Global Malaria Programme. All DHA/PPQ and CQ treatment doses were given under the direct supervision of study clinicians and study team members, whereas for AL only the morning dose was supervised, the evening dose was taken at home and patients were asked if they took the drug as instructed before administering the next dose. Patients were encouraged to eat fatty foods and expected to report completion of the second, evening AL dose.
All patients were observed for adverse reactions or vomiting for 60 min following treatment administration. Patients vomiting their medication within the first 30 min received a repeat full dose; patients vomiting within 30–60 min received half the original dose. Patients with P. vivax mono- or mixed infection during enrolment or follow-up were offered treatment with 14 days of primaquine (0.25 mg/kg) (Sanofi-Aventis, Bridgewater, NJ, US) as per the national treatment guideline for radical cure at the end of the follow-up period or upon reaching a study endpoint.
At enrolment, patients completed a medical examination and questionnaire, and a capillary blood sample was collected for blood film examination and haemoglobin measurement. In addition, three 50-μl capillary blood spots were stored on filter papers (Whatman 903 and Whatman 3; GE Healthcare Biosciences, Westborough, MA, US).
Patients were asked to return for routine assessment, follow-up medical exam, and blood film examination on days 1, 2, 3, 7, 14, 21, 28, 35, and 42. For the primary efficacy outcome, AL and CQ were assessed to day 28 and DHA/PPQ to day 42 as recommended by WHO. Polymerase chain reaction (PCR) correction was only done to day 28 for AL and CQ arms. Patients were also asked to return to the clinic if they had signs or symptoms consistent with malaria or any adverse events on non-scheduled follow up days. Adverse events and concomitant medications were recorded at every visit, and repeat haemoglobin concentration was measured on days 0, 14, 28 and 42.
Classification of treatment outcome
According to WHO recommendations, treatment responses were classified as early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), or ACPR for P. falciparum and P. vivax .
Early treatment failure
Development of danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitaemia; parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature; parasitaemia on day 3 with axillary temperature ≥ 37.5 °C; and parasitaemia on day 3 ≥ 25% of count on day 0.
Late clinical failure
Development of danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 28 in patients who did not previously meet any of the criteria of early treatment failure; and presence of parasitaemia on any day between day 4 and day 28 with axillary temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure.
Late parasitological failure
Presence of parasitaemia on any day between day 7 and day 28 with axillary temperature < 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure.
Adequate clinical and parasitological response
Absence of parasitaemia on day 28 or 42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of ETF, LCF or LPF.
The primary endpoints were PCR-corrected ACPR on day 28 for AL and CQ and day 42 for DHA/PPQ. Other outcomes were loss to follow-up and withdrawals which included protocol violation, withdrawal of consent/assent, interference (taking another drug with anti-malarial activity), and failure to complete study treatment (including persistent vomiting, concomitant disease, mixed infection).
Blood samples collected by finger prick from febrile outpatients were stained by 10% Giemsa for 10–15 min for initial screening. Blood films were examined by two microscopists and all slides were read independently. When the patient was enroled, and at subsequent follow-up visits, thick and thin blood smears were prepared on a single slide for parasite detection and species identification. Slides were stained by 3% Giemsa for 45 min, and then parasites were counted on thick films as the number of asexual parasites per 200 white blood cells (or per 500, if the count was < 10 parasites/200 white blood cells). A smear was declared negative if no parasites were seen after 1000 white blood cells were counted. The presence of gametocytes at enrolment or during follow-up was recorded. Asexual parasite density per microlitre (μL) was calculated on the assumption of 8000 leucocytes per μL blood. All collected slides were cross-checked by WHO-certified microscopists (Adama Malaria Control Centre, Ethiopia) after the study. If the two parasitaemia readings were in agreement (difference in parasite densities < 50%), the average results were recorded. If the two counts were discordant in terms of parasite species or density by > 50%, then a third, independent microscopist re-examined the blood slides. For parasite positivity and species, two concordant results were considered the final result, while for parasite density, the average of the two closest estimates of parasitaemia was considered final.
Haemoglobin was measured from finger prick blood samples using a portable spectrophotometer (HemoCue, Ängelholm, Sweden) on days 0, 14, 28, and 42.
In order to differentiate recrudescence from re-infection, blood samples were collected on filter paper from a finger-prick on day 0 and on the day of parasite recurrence (day 7 onwards) for genotyping. Specimens were dried, stored in individual plastic bags with desiccants and protected from light, humidity, and extreme temperatures. The samples were genotyped at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, GA, USA. Each dried blood spot was punched with a sterile puncher and DNA from the punched spots were extracted using QIAamp® DNA Mini Kit (QIAGEN, Valencia, CA). For P. falciparum positive samples, seven neutral microsatellite markers (C2M34-313 on chromosome 2, C2M69-383 on chromosome 3, Poly-α on chromosome 4, TA1 and TAI09 on chromosome 6, 2490 on chromosome 10, and PfPK2 on chromosome 12) were analyzed as previously published . Microsatellite allele size and peak height (above 200 fluorescent units) were scored by GeneMarker v3.0.0 (SoftGenetics, PA, USA) from all seven markers. For P. vivax samples, seven microsatellite markers (3.502 on chromosome 3, MS2 and MS038 on chromosome 6, 10.29 on chromosome 10, 11.162 and MS6 on chromosome 11, and 12.335 on chromosome 12) were genotyped using published protocols [27, 28]. Background allele frequencies were determined from day 0 of a randomly selected 20% of samples from participants classified as ACPR. A previously described Bayesian statistical algorithm was used to assign a posterior probability of recrudescence to each case of recurrent parasitaemia  (Additional file 1).
All samples of P. falciparum recurrence, in addition to 20% of randomly selected day zero samples, were analysed for polymorphisms in the pfk13 propeller domain and pfmdr1 by performing Sanger sequencing . The pfK13 domain from codon positions 389–649 was assessed for presence of mutations known to be associated with artemisinin resistance as recommended by the WHO (N458Y, Y493H, R539T, I543T, C580Y, F446I, M476I, R561H, P553L) using a previously published method [30,31,32]. Five mutations in the pfmdr1 gene that are associated with resistance to different anti-malarial drugs were analysed at codons N86Y, Y184F, S1034C, N1042D, D1246Y as reported previously .
Assuming an ACPR rate of 95% and 95% confidence interval and 5% precision, a total of 73 patients per arm were calculated. Factoring in 20% loss to follow-up and withdrawals, 88 patients per each arm for a total of 352 patients across the four arms were targeted.
SAS 9.3 (Cary, NC) and the WHO Excel-based data entry and analysis tool were used for analysis . Data were analysed as per-protocol and Kaplan–Meier (survival) analysis methods. Patients who were withdrawn from the study or lost to follow-up were excluded from the per-protocol analysis; patients with PCR-confirmed reinfection were excluded from the PCR-corrected per-protocol analysis. For the survival analysis, patients who were lost to follow-up or withdrawn were censored on the last day of follow-up according to the timetable. Reinfections were censored on the last day of follow up in the PCR-corrected survival analysis.
The study protocol was approved by the Ethiopian Public Health Institute (EPHI), the National Ethical Committee in Ethiopia (3.10/171/2016) and FMHACA. In addition, the study was reviewed and approved by the Institutional Review Boards (IRBs) of Columbia University and the U.S. CDC (#6892). Written consent and/or assent was obtained from study participants or their guardians.
A total of 10,903 febrile patients presented to Felegeselam and Arbaminch Health Centres during the study period. Of these, 907 patients were screened in the laboratory. Four hundred twenty-four patients mono-infected with either P. falciparum or P. vivax fulfilled the inclusion criteria. As the number of cases per each site was not sufficient for per site analysis, data was pooled from the two study sites (supplementary tables 1–3 are included to show per site analysis). One hundred and eighty-one P. falciparum-infected patients were enroled in AL (n = 106) and DHA/PPQ (n = 75) arms. One hundred and ninety-eight P. vivax-infected patients were enroled in the CQ (n = 142) and DHA/PPQ (n = 56) arms. Most P. falciparum infected patients were enroled in Arbaminch (n = 156) and most P. vivax patients were enroled at Pawe (n = 144) health centres. A total of 101 (95.3%) P. falciparum patients in the AL arm and 132 (93.0%) patients in the P. vivax-CQ arm reached the 28-day primary endpoint; 68 (90.7%) P. falciparum and 49 (87.5%) P. vivax patients in the DHA/PPQ arms completed the 42 days of follow up (Fig. 2). The study was terminated at the end of the transmission season despite not reaching the targeted sample size for each site.
The median parasitaemia at day zero were 18,255 for AL, and 8,755 for DHA/PPQ arms for P. falciparum and 10,051 for CQ and 5,373 for DHA/PPQ arms for P. vivax. The median age was 15 years (range: 1–57) in the P. falciparum-AL arm and 25 years (18–65) in the P. falciparum-DHA/PPQ arm. The median age was 14 (1–70) in the P. vivax-CQ arm and 23 (18–70) in the P. vivax-DHA/PPQ arm. Most of the study participants were male (56–71%) in all arms. Forty two percent of patients enroled had gametes: 77% (152/198) P. vivax-infected and 5% (9/181) P. falciparum-infected patients had gametes. The median day 0 gametocyte density for P. falciparum was zero per µl for both arms but with a range of 0–3,520 in the DHA/PPQ arm; for P. vivax, the median was 401 per µl (range: 0–14,023) in the CQ arm and 320 per µl (range: 0–10,000) in the DHA/PPQ arm. Median day zero haemoglobin levels were similar across the four arms (Table 1).
The treatment outcomes for day 28 and 42 (limited to DHA/PPQ) are shown in Table 2. Using the per-protocol analysis, the 28-day follow-up ACPR for P. falciparum was 98% (95% CI: 93–100) for AL and 100% for DHA/PPQ. The 42-day follow-up ACPR for DHA/PPQ was 100%. Two failures in the AL arm were observed, one on day 21 and one on day 28. Both failures were confirmed to be re-infection by PCR, one with a 33% and one with 11% probability of recrudescence. The 28-day follow-up PCR-corrected ACPR for CQ against P. vivax was 98% (95% CI: 94–100), with the two PCR-corrected samples with probability of recrudescence above 99%. The 42-day follow-up ACPR for DHA/PPQ against P. vivax was 100% (95% CI 93–100). The Kaplan–Meier analysis is presented to show the censored estimates (Table 2) and microsatellite data are included as a supplement. Although not a primary outcome, 42-day follow up ACPR for CQ was 82% with Felgeselam Health Centre reporting 86.0% and Arbaminch 97.7% (data not shown).
Table 3 presents data for secondary outcomes including day three parasite clearance. Asexual parasite clearance by day three was observed in all participants in all the arms by day three. One (1%) asexual parasite on the DHA/PPQ against P. falciparum arm and three (2%) asexual parasites on the CQ arm against P. vivax was observed on day two, that eventually cleared on day three. All patients cleared gametocytes. Two P. vivax-infected patients had gametocytes noted on day 28 in the CQ arm (Table 3). However, several patients in the CQ arm were observed to have gametes and gametocytes on day 35 (6%) and on day 42 (4%) (data not shown).
In all four arms, the study participants were afebrile by day two. In both DHA/PPQ arms, average haemoglobin levels initially decreased but then recovered by day 42 to levels higher than those on day zero (Table 3). No serious adverse events were observed and no cardiovascular-related complaints were reported.
A total of 50 Day 0 samples, 30 from the P. falciparum-AL arm and 20 from the P. falciparum-DHA/PPQ arm were sequenced for polymorphisms in the pfk13 and pfmdr1 genes. In the pfk13 gene, nine haplotypes associated with artemisinin resistance were assessed (N456Y, Y493H, R539T, I543T, C580Y, F446I, M476I, R561H, P553L), and no resistance-related mutants were observed. One pfk13 non-synonymous mutation, E433D was observed in a day zero sample from Pawe. In the pfmdr1 gene, nine haplotypes were assessed, and the following mutations were observed: in one sample N86Y (2%), in two samples Y184Y/F (4%), in 35 samples Y184F (73%), and in one sample S1034N (2%). In total, 24/30 (80%) samples showed pfmdr1 mutant haplotypes in the P. falciparum-AL arm and 15/20 (75%) samples in the P. falciparum-DHA/PPQ arm. Prevalence and polymorphism of resistance markers are shown in Table 4.
The current study reported the therapeutic efficacy of AL and DHA/PPQ against uncomplicated P. falciparum, and CQ and DHA/PPQ against uncomplicated P. vivax. All the study drugs showed high efficacy within their respective follow-up period, demonstrating that the first-line species-specific malaria treatments are efficacious in the study sites of Ethiopia. The PCR-corrected per-protocol analysis demonstrated 100% efficacy of AL against P. falciparum for the 28-day follow-up outcome and a 100% efficacy of DHA/PPQ against P. falciparum in the 42-day follow-up outcome. In a similar fashion, the PCR-corrected per-protocol analysis demonstrated 98% efficacy of CQ against P. vivax for the 28-day follow-up outcome, and 100% efficacy of DHA/PPQ for the 42-day follow-up outcome.
The high efficacy reported for AL and CQ was consistent with previous studies in Ethiopia. Studies conducted since 2006 by EPHI and others have shown a high efficacy of AL against P. falciparum, confirming the drug remains well-tolerated and effective for the intended use in Ethiopia [4, 5, 8,9,10, 15, 19, 34, 35]. The exception was a non-peer reviewed study in 2010 that reported 7.2% failure (92.8% uncorrected ACPR) of AL at the Shele Health Centre, Arbaminch Zuria in Southwest Ethiopia which is located close to the Arbaminch Health Centre in the current study (Moges Kassa personal communication). Although the lower efficacy result from this site with anecdotal reports of wide herbal artemisinin use was concerning, this study along with others have shown high efficacy of ACTs. DHA/PPQ has not been used for malaria treatment in the public sector in Ethiopia. However, the findings are consistent with previous reports of high efficacy for both P. falciparum and P. vivax from elsewhere and the extended protection to day 42 attributed to piperaquine’s longer half-life [21,22,23,24,25].
Asexual and sexual parasites and fever were cleared by day three in all arms, reaffirming the sensitivity of the parasites circulating in the population to the respective drugs, especially the artesiminin component . Gametocytes were cleared by day three in all four arms; however, two patients with gametocytes were observed on day 28 in the P. vivax-CQ arm. No presence of gametocytes was observed in either of the P. falciparum and P. vivax DHA/PPQ arms up to 42-day follow-up by microscopy, contrasting with other data indicating that piperaquine may encourage gametocyte production when provided as mono-therapy . As low density parasites may not be detected by microscopy; a sensitive quantitative nucleic acid detection method may be required to better understand parasite dynamics post-treatment [37,38,39]. The hematological profile of the participants in the DHA/PPQ arms showed a general initial decrease in haemoglobin levels with recovery by day 42 to levels similar to day 0 values, which is consistent with prior studies in Ethiopia as well as the findings of a systematic review of DHA/PPQ treatment for P. vivax [8, 40]. All study drugs were shown to be generally well-tolerated with no serious adverse events observed.
Among the 50 P. falciparum samples sequenced for the PfK13 gene, none had a mutation associated with artemisinin resistance. These results were in contrast with previous studies that showed the presence of the k13 markers in Ethiopia and elsewhere in Africa [12, 41, 42]. None of the isolates reported in Africa were related to treatment failure, except the R561H haplotype reported from Rwanda, which was associated with confirmed delayed parasite clearance [12, 42]. R561H was not detected in the current study. This study reported a considerable number of the samples (36/50) with the NFD haplotype. Certain Pfmdr1 haplotypes have been associated with CQ, mefloquine, quinine, other quinolones, and/or artemisinin resistance [26, 31]. A case study based on an Italian tourist who travelled to Africa, including Ethiopia, reported treatment failure after DHA/PPQ with presence of pfmdr1 markers. The markers were assumed to be related with piperaquine, suggesting the need for continuous molecular surveillance for anti-malarial resistance .
Chloroquine resistance against P. vivax has been reported in Ethiopia and in Southeast Asia [15, 34, 42]. Despite the six decades of use in Ethiopia, the 98% ACPR at day 28 and the high parasite clearance rates on days 2 and 3 for CQ are encouraging . The lower and site-specific differences noted on the 42-day ACPR is likely a reflection of different local transmission levels as these recurrences are due to relapses or reinfection. The addition of primaquine for radical cure which is now included in the revised national malaria treatment guideline of Ethiopia will not only address relapse prevention but should further enhance the schizonticidal efficacy of CQ [8, 44].
The high efficacy of DHA/PPQ has been reported in numerous African countries and Southeast Asia. Although only studied in adult subjects, this report is consistent with other studies showing high efficacy and no serious adverse events against either P. falciparum or P. vivax . DHA/PPQ with its longer prophylactic tail has been modelled to be more cost-effective and superior in reducing clinical incidence and malaria prevalence than AL as first-line treatment in higher transmission settings; however, its impact in lower transmission settings like Ethiopia is less clear [45, 46]. Nonetheless, DHA/PPQ is the first line treatment for P. falciparum in neighbouring Somalia and Eritrea [21, 24]. The high efficacy for both P. falciparum and P. vivax, as well as the long half-life, makes DHA/PPQ a good option for treatment and chemoprevention strategies in malaria elimination settings in Ethiopia and elsewhere .
Limitations to this current study are several including the lower than targeted enrolment for the DHA/PPQ arms due to enrolment not being extended past the high transmission season. The inclusion criteria for P. falciparum-infected patients were reduced to 500 parasites/ul in order to increase enrolment rates; however, only nine patients had parasitaemia levels between 500 and 1000 parasites/ul and likely did not affect the efficacy outcomes greatly. The study only enroled adult patients (18 years and above) for the DHA/PPQ arm which resulted in lower baseline parasitaemia in the DHA/PPQ arms, increased median age for the study overall, lower enrolment and limited generalizability to younger age groups. The study was powered for efficacy outcomes per arm and cannot be used to compare results between arms. In addition, insufficient numbers of patients were enroled in a given health centre necessitating pooling of data from two study sites which resulted in not being able to provide site-specific efficacy estimates. Though sample size was not achieved, site-specific outcomes have been included which showed no major difference from the pooled analysis for the primary outcomes (Additional file 2: Tables S1–S4). Data on the types and prevalence of adverse events was not presented as the study team erroneously recorded ongoing presenting symptoms as adverse events; however, there were no serious adverse events or unusual adverse events e.g. cardiac complaints. Another study limitation was that the second AL dose was unobserved and only confirmed verbally during the next visit which might have resulted in lower adherence in the AL arm. Lastly, the genotype investigation was limited to 50 samples and resistance markers for piperaquine and CQ markers were not included. Studies by Mohammed et al. showed high genetic diversity and multiplicity of infection in samples collected from Northwest and Southwest Ethiopia, reinforcing the need for careful interpretation of genotype results [47,48,49,50,51]. As next steps, consideration should be given to conducting therapeutic efficacy studies with genomic investigations to enable the early detection of resistance, inclusion of age groups below 18 years of age in subsequent studies of DHA/PPQ, powered sample size for between group comparisons and evaluation of other WHO-recommended drugs to expand the anti-malarial arsenal for Ethiopia and beyond.
This study demonstrated high therapeutic efficacy for the anti-malarial drugs currently used by the malaria control programme in Ethiopia and provides information on the efficacy of DHA/PPQ for the treatment of P. falciparum and P. vivax as an alternative option. The study reported high efficacy of AL and CQ against uncomplicated P. falciparum and P. vivax infections, respectively, over 28 days of follow up. The study provided evidence that the drugs remain efficacious despite decades of use as shown by rapid fever and parasitaemia clearance by day three and the absence of relevant Pfk13 haplotypes for artemisinin. The high efficacy for DHA/PPQ (100%) over the 42 days of follow up for both P. falciparum and P. vivax supports the potential use of DHA/PPQ as an additional option for the treatment and chemoprevention of both P. falciparum and P. vivax in Ethiopia. Further comparisons investigating duration of protection and cost- effectiveness between DHA/PPQ, AL, and CQ in Ethiopia are warranted.
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention or the U.S. Agency for International Development.
Use of trade names is for identification only and does not imply endorsement by the U.S. Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry, the U.S. Public Health Service, or the U.S. Department of Health and Human Services.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Site specific results and genotyping data are included as supplemental information.
Adequate Clinical and Parasitological Response
Artemisinin-based Combination Therapy
Ethiopian Public Health Institute
Early treatment failure
Food, Medicine and Health Care Administration and Control Authority of Ethiopia
Ministry of Health Federal Democratic Republic of Ethiopia. Ethiopian Malaria Review Document. Addis Ababa, Ethiopia; 2020.
Ministry of Health Federal Democratic Republic of Ethiopia. National Malaria Elimination Roadmap. National Malaria prevention, control and elimination programme; Disease Prevention and Control Directorate; 2016.
WHO. Guideline for the treatment of malaria. Geneva, World Health Organization, 2015.
Ministry of Health Federal Democratic Republic of Ethiopia. Malaria diagnosis and treatment guidelines for health workers in Ethiopia. Addis Ababa; 2004.
Wudneh F, Assefa A, Nega D, Mohammed H, Solomon H, Kebede T, et al. Open-label trial on efficacy of artemether/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district. Northwestern Ethiopia Ther Clin Risk Manag. 2016;12:1293–300.
Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T. Therapeutic efficacy of artemether/lumefantrine (Coartem®) against Plasmodium falciparum in Kersa. South West Ethiopia Parasit Vectors. 2010;3:1.
Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14: e1002299.
Nega D, Assefa A, Mohamed H, Solomon H, Woyessa A, Assefa Y, et al. Therapeutic efficacy of artemether-lumefantrine (Coartem®) in treating uncomplicated P. falciparum malaria in Metehara, Eastern Ethiopia: regulatory clinical study. PLoS ONE. 2016;11:e0154618.
Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE. 2017;12: e0176004.
Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602–8.
Getachew S, Thriemer K, Auburn S, Abera A, Gadisa E, Aseffa A, et al. Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar J. 2015;14:525.
Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, et al. Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014;13:244.
Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929–38.
Assefa M, Eshetu T, Biruksew A. Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Hossana Health Care Centre, southern Ethiopia. Malar J. 2015;14:458.
Shumbej T, Jemal A, Worku A, Bekele F, Weldesenbet H. Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia. BMC Infect Dis. 2019;19:413.
Commons RJ, Simpson JA, Thriemer K, Abreha T, Adam I, Anstey NM, et al. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: a systematic review and individual patient data meta-analysis. PLoS Med. 2019;16: e1002928.
Liu H, Yang H, Tang L, Li X, Huang F, Wang J, et al. In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013. Malar J. 2015;14:47.
Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18:231.
Baiden R, Oduro A, Halidou T, Gyapong M, Sie A, Macete E, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J. 2015;14:160.
Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, et al. Molecular profile of malaria drug resistance markers of Plasmodium falciparum in Suriname. Antimicrob Agents Chemother. 2017;61:e02655-e2716.
Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096–100.
Talundzic E, Chenet SM, Goldman IF, Patel DS, Nelson JA, Plucinski MM, et al. Genetic analysis and species specific amplification of the artemisinin resistance-associated kelch propeller domain in P. falciparum and P. vivax. PLoS ONE. 2015;10:e0136099.
Vinayak S, Alam MT, Sem R, Shah NK, Susanti AI, Lim P, et al. Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J Infect Dis. 2010;201:1551–60.
Pasay CJ, Rockett R, Sekuloski S, Griffin P, Marquart L, Peatey C, et al. Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. J Infect Dis. 2016;214:105–13.
Harris I, Sharrock WW, Bain LM, Gray K-A, Bobogare A, Boaz L, et al. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J. 2010;9:254.
Leonard CM, Mohammed H, Tadesse M, McCaffery JN, Nace D, Halsey ES, et al. Missed Plasmodium falciparum and Plasmodium vivax mixed infections in Ethiopia threaten malaria elimination. Am J Trop Med Hyg. 2021;106:667–70.
Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Med. 2019;17:151.
Gobbi F, Buonfrate D, Menegon M, Lunardi G, Angheben A, Severini C, et al. Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia. Malar J. 2016;15:525.
Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in african children: a cost-effectiveness analysis. PLoS ONE. 2014;9:e95681.
Mohammed H, Hassen K, Assefa A, Mekete K, Tadesse G, Taye G, et al. Genetic diversity of Plasmodium falciparum isolates from patients with uncomplicated and severe malaria based on msp-1 and msp-2 genes in Gublak. North West Ethiopia Malar J. 2019;18:413.
Mohammed H, Assefa A, Chernet M, Wuletaw Y, Commons RJ. Genetic polymorphisms of Plasmodium falciparum isolates from Melka-Werer, North East Ethiopia based on the merozoite surface protein-2 (msp-2) gene as a molecular marker. Malar J. 2021;20:85.
Mohammed H, Kassa M, Assefa A, Tadesse M, Kebede A. Genetic polymorphism of Merozoite Surface Protein-2 (MSP-2) in Plasmodium falciparum isolates from Pawe District. North West Ethiopia PLoS ONE. 2017;12: e0177559.
Mohammed H, Mindaye T, Belayneh M, Kassa M, Assefa A, Tadesse M, et al. Genetic diversity of Plasmodium falciparum isolates based on MSP-1 and MSP-2 genes from Kolla-Shele area, Arbaminch Zuria District, southwest Ethiopia. Malar J. 2015;14:73.
We would like to thank Dr. Udhayakumar Venkatachalam, Dr Naomi Lucchi and Dr. Eric S. Halsey with the Malaria Branch, U.S. Centers for Disease Control and Prevention for their expertise and support for this project. We would also like to acknowledge the U.S. President’s Malaria Initiative for their financial and technical support of this project and the study team members and study participants.
The study was funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria via the Federal Ministry of Health in Ethiopia, U.S. President’s Malaria Initiative and World Health Organization. JH, HT, and MWM receive salary support from the U.S. President’s Malaria Initiative.
Authors and Affiliations
Ethiopian Public Health Institute, Addis Ababa, Ethiopia
Conceived the study, compiled the protocol, designed the experiments and led data collection: AA, HM, MT, YT, SG, JH, and AAM. Performed genotyping: Adugna A, SSS, ZZ, BE. Analyzed the data: UV, Anjoli A, AA, SSS, ZZ, NWL, and LFM. Assisted study implementation: HH, WB, KE, BHA, HT, MM, DD, MH, HS, AA. Critically reviewed and contributed to writing: HM, MM, JH, and LFM. Drafted the manuscript: AA. All authors read and approved the final manuscript.
The study protocol was approved by the Ethiopian Public Health Institute (EPHI), the National Ethical Committee in Ethiopia (3.10/171/2016) and the Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA). The study was reviewed and approved by the Institutional Review Boards (IRBs) of Columbia University and the U.S. Centers for Disease Control and Prevention (#6892). Written consent and/or assent was obtained from study participants or their guardians.
Consent for publication
The authors declare that they have no competing interests.
Data availability statement
Data set used is available from the Ethiopian Public Health Institute and/or the curresponding author on modest
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. study profile and characteristics by site. Table S2. Treatment outcomes per site. Table S3. Proportion of slides negative for asexual parasites on day 2 and 3 per site. Table S4. Treatment outcome per site.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Assefa, A., Mohammed, H., Anand, A. et al. Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia.
Malar J21, 359 (2022). https://doi.org/10.1186/s12936-022-04350-z